• 1
    Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 14941500.
  • 2
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359362.
  • 3
    Abel M, Sène D, Pol S, Bourlière M, Poynard T, Charlotte F, et al. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. HEPATOLOGY 2006; 44: 16071616.
  • 4
    Lauer D, Müller R, Cott C, Otto A, Naumann M, Birkenmeier G. Modulation of growth factor binding properties of alpha2-macroglobulin by enzyme therapy. Cancer Chemother Pharmacol 2001; 47( Suppl): S4S9.
  • 5
    Ker CG, Chen HY, Juan CC, Lo HW, Shen YY, Chen JS, et al. Role of angiogenesis in hepatitis and hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 646650.
  • 6
    García-Monzon C, Sanchez-Madrid F, García-Buey L, García-Arroyo A, García-Sánchez A, Moreno-Otero R. Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology 1995; 108: 231241.
  • 7
    Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91: 13541360.
  • 8
    Poon RT, Lau CP, Ho JW, Lau C, Ng IO, Fan ST. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003; 29: 53395345.
  • 9
    Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999; 103: 341345.
  • 10
    Tol M, Bando H, Kuroi K. The predictive value of angiogenesis for adjuvant therapy in breast cancer. Breast Cancer 2000; 7: 311314.
  • 11
    Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J, et al. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 2001; 182: 298304.
  • 12
    Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 2001; 116: 838845.
  • 13
    Stein I, Neeman M, Shweiki D, Itin A, Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995; 15: 53635368.
  • 14
    Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843845.
  • 15
    Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells: possible roles of SP-1. J Biol Chem 1996; 271: 2822028228.
  • 16
    Jeon SH, Chae BC, Kim HA, Seo GY, Seo DW, Chun GT, et al. Mechanisms underlying TGF-beta1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J Leukoc Biol 2007; 81: 557566.
  • 17
    Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117129.
  • 18
    De Bleser PJ, Niki T, Rogiers V, Geerts A. Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J Hepatol 1997; 26: 886893.
  • 19
    Kinnman C, Andersson U, Hultcrantz R. In situ expression of transforming growth factor-beta1–3, latent transforming growth factor-beta binding protein and tumor necrosis factor-alpha in liver tissue from patients with chronic hepatitis. Scand J Gastroenterol 2000; 35: 12941300.
  • 20
    Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991; 65: 11051113.
  • 21
    Hassan M, Ghozlan H, Abdel-Kader O. Activation of RB/E2F signaling pathway is required for the modulation of hepatitis C virus (HCV) core protein-induced cell growth in liver and non-liver cells. Cell Signal l 2004; 16: 13751385.
  • 22
    Hassan M, Ghozlan H, Abdel-Kader O. Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the modulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)- mediated cell growth in hepatocyte and non-hepatocyte derived cells. Virology 2005; 333: 324336.
  • 23
    Hassan M, Selimovic D, Ghozlan H, Abdel-Kader O. Induction of high-molecular-weight (HMW) tumor necrosis factor (TNF) alpha by hepatitis C virus (HCV) non-structural protein 3 (NS3) in liver cells is AP-1 and NF-kappaB-dependent activation. Cell Signal 2007; 19: 301311.
  • 24
    Ray RB, Lagging LM, Meyer K, Steele R, Ray R. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995; 37: 209220.
  • 25
    Ray RB, Lagging LM, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 1996; 70: 44384443.
  • 26
    Ray RB, Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997; 272: 1098310986.
  • 27
    Srinivas RV, Ray RB, Meyer K, Ray R. Hepatitis C virus core protein inhibits human immunodeficiency virus type 1 replication. Virus Res 1996; 45: 8792.
  • 28
    Erhardt A, Hassan M, Heintges T, Häussinger D. Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line. Virology 2002; 292: 272284.
  • 29
    Desmet VJ. Chronic hepatitis. In: McGee JO, Isaacson PG, Wright NA, ed. Oxford Textbook of Pathology. Volume 2A. 1st ed. Oxford: Oxford University Press; 1992: 13131324.
  • 30
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981; 1: 431435.
  • 31
    Selimovic D, Hassan M, Haikel Y, Hengge UR. Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2. Cell Signal 2007; 20: 311322.
  • 32
    Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol 2004; 57: 867871.
  • 33
    Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791796.
  • 34
    Hassan M, Alaoui A, Feyen O, Mirmohammadsadegh A, Essmann F, Tannapfel A, et al. The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways. Oncogene 2008; 27: 45574568.
  • 35
    Tan EL, Selvaratnam G, Kananathan R, Sam CK. Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. BMC Cancer 2006; 6: 227.
  • 36
    Noma T, Glick AB, Geiser AG, O'Reilly MA, Miller J, Roberts AB, et al. Molecular cloning and structure of the human transforming growth factor-beta 2 gene promoter. Growth Factors 1991; 4: 247255.
  • 37
    Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 2000; 60: 58795886.
  • 38
    Beisner J, Buck MB, Fritz P, Dippon J, Schwab M, Brauch H, et al. A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer. Cancer Res 2006; 66: 75547561.
  • 39
    Wilder PJ, Desler MM, Nowling TK, Rizzino A. Isolation and characterization of the murine transforming growth factor-beta2 promoter. Gene 2001; 270: 201209.
  • 40
    Pfafflin A, Brodbeck K, Heilig CW, Häring HU, Schleicher ED, Weigert C. Increased glucose uptake and metabolism in mesangial cells overexpressing glucose transporter 1 increases interleukin-6 and vascular endothelial growth factor production: role of AP-1 and HIF-1alpha. Cell Physiol Biochem 2006; 18: 199210.
  • 41
    Di Carlo I, Fraggetta F, Lombardo R, Azzarello G, Vasquez E, Puleo S. CD 34 expression in chronic and neoplastic liver diseases. Panminerva Med 2002; 44: 365367.
  • 42
    Ziche M, Gullino PM. Angiogenesis and neoplastic progression in vitro. J Natl Cancer Inst 1982; 69: 483487.
  • 43
    Gullino PM, Ziche M, Alessandri G. Gangliosides, copper ions and angiogenic capacity of adult tissues. Cancer Metastasis Rev 1990; 9: 239251.
  • 44
    Folkman J. How the field of controlled-release technology began, and its central role in the development of angiogenesis research. Biomaterials 1990; 11: 615618.
  • 45
    Folkman J. Growth control in capillary endothelium. Dev Biol 1985; 3: 101110.
  • 46
    Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032: 89118.
  • 47
    Rizzino A. Transforming growth factor-beta: multiple effects on cell differentiation and extracellular matrices. Dev Biol 1988; 130: 411422.
  • 48
    But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008; 14: 16521656.
  • 49
    Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000; 124: 10611065.
  • 50
    Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992; 148: 14041410.
  • 51
    de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlüsener H, et al. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J 1987; 6: 36733677.
  • 52
    Yamamoto T, Akisue T, Marui T, Fujita I, Matsumoto K, Hitora T, et al. Expression of transforming growth factor beta isoforms and their receptors in malignant fibrous histiocytoma of soft tissues. Clin Cancer Res 2004; 10: 58045807.
  • 53
    Lee SY, Chuang JH, Huang CC, Chou MH, Wu CL, Chen CM, et al. Identification of transforming growth factors actively transcribed during the progress of liver fibrosis in biliary atresia. J Pediatr Surg 2004; 39: 702708.
  • 54
    Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res 2007; 84: 812822.
  • 55
    Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo KT, Yeo TK, et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci 1992; 667: 101111.
  • 56
    Nasimuzzaman M, Waris G, Mikolon D, Stupack DG, Siddiqui A. Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. J Virol 2007; 81: 1024910257
  • 57
    Hoglinger GU, Breunig JJ, Depboylu C, Rouaux C, Michel PP, Alvarez-Fischer D, et al. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci U S A 2007; 104: 35853590.
  • 58
    Chaussepied M, Ginsberg D. Transcriptional regulation of AKT activation by E2F. Mol Cell 2004; 16: 831837
  • 59
    Chaussepied M, Ginsberg D. E2F and signal transduction pathways. Cell Cycle 2005; 4: 392396.